CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 126 enrolled
Drug / intervention
Fingolimod 0.5 mgdrug
Likely dose
Fingolimod 0.5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02373098
NCT02373098Phase 4Completed
CompareCT.gov

Effects of Fingolimod (Gilenya®) on Cytokine and Chemokine Levels in Relapsing Remitting Multiple Sclerosis Patients

Novartis Pharmaceuticals·interventional·Posted Feb 26, 2015·Updated Sep 30, 2019

In Brief

A Phase 4 clinical trial evaluating Fingolimod 0.5 mg for Relapsing Remitting Multiple Sclerosis. Completed, enrolled 126 participants across 3 sites.

Detailed Summary

The main purpose of this study was to measure the serum levels of cytokines and chemokines that are known to increase during multiple sclerosis relapses. Cytokines are a broad and loose category of small proteins that are important in cell signaling. The second purpose of the study was to test the cytokine/chemokine changes measured in the 3rd and 6th months on the efficacy parameters.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRelapsing Remitting Multiple Sclerosis
CountriesTurkey (Türkiye)
Collaborators--

Timeline

Phase 4CompletedFinished
201520162017201820192020202120222023202420252026
First PostedFeb 26, 2015
Enrollment StartMar 31, 2015
Primary CompletionJan 18, 2017
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 11.3 years ago

Interventions

Fingolimod 0.5 mgdrug

66 relapsing remitting MS (RRMS) patients were recruited. Patients who met all inclusion and none of the exclusion criteria were treated by Fingolimod 0.5 mg.